This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|June 13, 2022
Yourway Announces New European Depot in Dublin
Author(s)BioPharm International Editors
Yourway intends to construct a new manufacturing facility in the Dublin Airport Logistics Park.
Advertisement
Yourway, an integrated courier and clinical packaging company, announced the construction of a new flagship European depot in Dublin, Ireland on June 8, 2022. The new good manufacturing practice facility will support Yourway’s clinical trials offering, including courier services, primary and secondary packaging, and temperature-controlled storage.
According to a company press release, Yourway chose the Dublin Airport Logistics Park site because it’s convenient for major pharma and biopharma companies in Ireland. The facility will also offer easy access to a significant domestic clinical trials market. It is scheduled to be audit ready by Q4 2022.
“With Ireland’s strength in biopharma, Yourway has operated there for over 15 years, which contributed to our decision to build our flagship depot in Dublin,” said Gulam Jaffer, founder and president, Yourway, in the press release. “We’re anticipating notable market growth in Europe, and Yourway will be perfectly placed to support it.”
The site will be supported by the company’s other European depots in London, UK; Kyiv, Ukraine; Minsk, Belarus; and Moscow, Russia. The company’s global depot network exists across these locations as well as sites in 15 other countries across the world.
Source: Yourway
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5